210
Participants
Start Date
December 31, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Brincidofovir
Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
Mt. Sinai, New York
Columbia University, New York
Memorial Sloan Kettering Cancer Institute, New York
UPMC, Pittsburgh
Childrens Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
NIH, Bethesda
University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
Levine Children's Hospital Carolina Medical Center, Charlotte
Nationwide Children's Hospital, Columbus
Cleveland Clinic, Cleveland
Cincinnati Childrens Hospital, Cincinnati
University of Michigan, Ann Arbor
University of Iowa, Iowa City
Medical College of Wisconsin, Milwaukee
University of Minnesota, Minneapolis
University of Chicago, Chicago
St. Louis Children's Hospital, St Louis
Childrens Hospital LSU, New Orleans
UT MD Anderson Cancer Center, Houston
Children's Hospital of Colorado, Aurora
Intermountain BMT program LDS Hospital, Salt Lake City
Children's Hospital of LA, Los Angeles
UCLA Department of Medicine, Los Angeles
Loma Linda University Hospital, Loma Linda
CHOC Children's, Orange
Univeristy of San Francisco, San Francisco
Lucile Packard Children's Hospital, Stanford
Oregon Health and Science University, Portland
University of Washington-Fred Hutchinson Cancer Center, Seattle
Tufts Medical Center, Boston
Brigham and Womens Hospital, Boston
University of Nebraska Medical Center, Omaha
Hackensack University Medical Center, Hackensack
Cook Children's Medical Center, Fort Worth
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY